Menu
Back to User profile » Dr Chuanyong Guo
Papers published by Dr Chuanyong Guo:
The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
Li J, Guo C, Wu J
Drug Design, Development and Therapy 2021, 15:2619-2628
Published Date: 18 June 2021
Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C
Journal of Hepatocellular Carcinoma 2020, 7:271-288
Published Date: 29 October 2020
Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent
Li J, Guo C, Wu J
Drug Design, Development and Therapy 2020, 14:2275-2285
Published Date: 9 June 2020
Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
Liu T, Li S, Wu L, Yu Q, Li J, Feng J, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, Dai W, Fan X, Wu J, Guo C
Journal of Hepatocellular Carcinoma 2020, 7:19-31
Published Date: 18 February 2020
Bergenin Exerts Hepatoprotective Effects by Inhibiting the Release of Inflammatory Factors, Apoptosis and Autophagy via the PPAR-γ Pathway
Xiang S, Chen K, Xu L, Wang T, Guo C
Drug Design, Development and Therapy 2020, 14:129-143
Published Date: 13 January 2020
Beraprost sodium preconditioning prevents inflammation, apoptosis, and autophagy during hepatic ischemia-reperfusion injury in mice via the P38 and JNK pathways
Deng J, Feng J, Liu T, Lu X, Wang W, Liu N, Lv Y, Liu Q, Guo C, Zhou Y
Drug Design, Development and Therapy 2018, 12:4067-4082
Published Date: 29 November 2018
Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways
Feng J, Chen K, Xia Y, Wu L, Li J, Li S, Wang W, Lu X, Liu T, Guo C
Drug Design, Development and Therapy 2018, 12:1837-1853
Published Date: 22 June 2018
Salidroside pretreatment attenuates apoptosis and autophagy during hepatic ischemia–reperfusion injury by inhibiting the mitogen-activated protein kinase pathway in mice
Feng J, Zhang Q, Mo WH, Wu L, Li S, Li J, Liu T, Xu S, Fan X, Guo C
Drug Design, Development and Therapy 2017, 11:1989-2006
Published Date: 3 July 2017
Autophagy: a new target for nonalcoholic fatty liver disease therapy
Mao YQ, Yu FJ, Wang JB, Guo CY, Fan XM
Hepatic Medicine: Evidence and Research 2016, 8:27-37
Published Date: 24 March 2016
Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3
Li S, Xia Y, Chen K, Li J, Liu T, Wang F, Lu J, Zhou Y, Guo C
Drug Design, Development and Therapy 2016, 10:631-647
Published Date: 15 February 2016
Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy
Li J, Chen K, Li S, Feng J, Liu T, Wang F, Zhang R, Xu S, Zhou Y, Zhou S, Xia Y, Lu J, Zhou Y, Guo C
Drug Design, Development and Therapy 2016, 10:619-630
Published Date: 12 February 2016
Inhibitive effects of 15-deoxy-Δ12,14-prostaglandin J2 on hepatoma-cell proliferation through reactive oxygen species-mediated apoptosis
Chen K, Dai W, Wang F, Xia Y, Li J, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, Yin Q, Zheng Y, Abudumijiti H, Chen R, Lu J, Zhou Y, Guo C
OncoTargets and Therapy 2015, 8:3585-3593
Published Date: 1 December 2015
Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]
Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C
Drug Design, Development and Therapy 2015, 9:5947-5948
Published Date: 9 November 2015
Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C
Drug Design, Development and Therapy 2015, 9:5407-5419
Published Date: 30 September 2015
Ghrelin reduces liver impairment in a model of concanavalin A-induced acute hepatitis in mice
Mao YQ, Wang JB, Yu FJ, Cheng J, Li HQ, Guo CY, Fan XM
Drug Design, Development and Therapy 2015, 9:5385-5396
Published Date: 28 September 2015
Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
Zhang Y, Li S, He L, Wang F, Chen K, Li J, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Xia Y, Zhou Y, Lu J, Guo C
Drug Design, Development and Therapy 2015, 9:2757-2766
Published Date: 25 May 2015
Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis
Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y, Dai W, Wang F, Chen K, Li J, Wang C, Li S, Liu T, Abudumijiti H, Zhou Z, Wang J, Lu W, Wang J, Xia Y, Zhou Y, Lu J, Guo C
Drug Design, Development and Therapy 2015, 9:567-574
Published Date: 17 January 2015
Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis
Cheng P, Chen K, Xia Y, Dai WQ, Wang F, Shen M, Wang C, Yang J, Zhu R, Zhang H, Li JJ, Zheng Y, Wang J, Zhang Y, Lu J, Zhou YQ, Guo CY
Drug Design, Development and Therapy 2014, 8:1277-1286
Published Date: 9 September 2014